Low-Aggregating Protein A Resins: A Solution to the Aggregate Problem for Bispecific and Multispecific Antibodies?

In the downstream purification of biopharmaceuticals such as monoclonal antibodies, bispecific antibodies, and Fc-fusion proteins, Protein A affinity chromatography is widely recognized as the gold standard for capture. However, this classic process has a long-overlooked shortcoming—antibody aggregation—and the technological breakthroughs of low-aggregating Protein A resins/aggregation-reducing Protein A resins/activity-preserving Protein A resins are addressing this industry pain point from two dimensions—aggregation suppression and activity preservation—fundamentally reshaping the antibody purification capture process.

Aggregates are among the most common product-related impurities in antibody drug manufacturing. They not only reduce product purity and yield but also pose immunogenicity risks, making them a core concern for drug quality and safety. The traditional view holds that aggregate removal is the task of polishing steps, while the Protein A capture step is merely responsible for "capturing the target, not separating impurities." However, this understanding is being revisited—the advent of low-aggregating Protein A resins/aggregation-reducing Protein A resins has successfully shifted the aggregate control frontline forward to the antibody capture core step. Activity-preserving Protein A resins further extend the focus from "removing the bad" to "protecting the good"—by avoiding harsh acidic elution conditions, they maximize the preservation of the native conformation and biological function of antibody molecules.

I. Antibody Aggregation: A "Secondary Disaster" of Low-pH Elution

The causes of antibody aggregation are complex, but in the Protein A affinity chromatography step, low-pH elution is the most direct trigger.

Typical Protein A antibody affinity chromatography elution is usually performed under acidic conditions at pH 3.0–3.5. For structurally stable conventional monoclonal antibodies, brief acidic exposure is tolerable. However, for complex molecules such as bispecific antibodies, multispecific antibodies, and antibody fragments, low-pH conditions disrupt the native protein conformational equilibrium, induce exposure of internal hydrophobic regions, and cause entanglement into soluble or insoluble aggregates.

More concerning is the pH jump effect, which further exacerbates aggregation. The dramatic pH change during the transition from low-pH elution to neutralization is itself an independent aggregation-inducing factor, with side effects even greater than acid exposure alone. This means that even if an antibody can tolerate low pH, the post-elution neutralization step may still trigger aggregation, further amplifying process losses and quality risks.

Conventional Protein A resins have virtually no aggregate separation capability. Aggregate removal relies primarily on subsequent polishing steps such as ion exchange, hydrophobic interaction, or size-exclusion chromatography. However, this "post-hoc remediation" model has significant limitations: once aggregates form, the efficiency and yield of subsequent separation are severely compromised. It is precisely this long-standing process challenge that has driven the core technological innovation of low-aggregating Protein A resins and aggregation-reducing Protein A resins.

II. Two Technical Pathways for Low-Aggregating Protein A Resins

Two Paths to the Same Goal

Currently, the R&D iteration of aggregation-reducing Protein A resins is advancing along two core pathways: engineered ligand design and novel ligand specificity engineering. These two technological routes complement each other, enabling low-aggregating Protein A resins to form a complete product system adaptable to different antibody molecules.

2.1 Pathway 1: Engineered Ligand Design — "Gentle Release" at the Source

The fundamental cause of antibody aggregation induced by conventional Protein A resins is the excessively low elution pH. Therefore, the most direct strategy is to raise the elution pH, suppressing aggregate formation at the source through mild elution.

Through site-directed mutagenesis of key amino acid residues in the Protein A ligand, engineered ligands can maintain binding capacity under loading conditions while enabling antibody dissociation at higher pH. A representative resin of this pathway features a ligand engineered to achieve antibody/Fc-fusion protein elution at pH 4.6 and above. The mild elution environment ensures that antibodies remain under low-stress conditions throughout the purification process—this is precisely the core value of activity-preserving Protein A resins.

Studies have shown that, unlike conventional Protein A resins which generally lack aggregate separation capability, this low-aggregating Protein A resin can remove up to 70% of aggregates from the feed while maintaining good monomer recovery (data source: relevant academic studies). A systematic study published in Protein Expression and Purification in 2025 compared the performance of high-pH elution resins against conventional resins across four case studies, confirming that aggregation-reducing Protein A resins of this type significantly outperform conventional resins in both aggregate and HCP clearance.

2.2 Pathway 2: Novel Ligand Specificity — Selective "Separation" of Aggregates

If Pathway 1 aims to "avoid aggregate formation" through mild elution, Pathway 2 takes a different innovative approach—without changing the elution pH, it alters the binding specificity of the ligand to enable the resin itself to distinguish between target antibodies and aggregates.

A representative resin of this pathway exhibits affinity exclusively for the VH3 domain. Its ligand has been engineered to bind only to the VH3 domain, rather than the conventional Fc+VH3 dual-binding mode of traditional Protein A. For byproducts lacking the VH3 domain (such as half-antibodies and homodimers), the resin does not bind, thereby achieving simultaneous separation of the target product from byproducts. Studies have demonstrated that this VH3-specific low-aggregating Protein A resin significantly outperforms conventional Protein A resins in aggregate separation capability.

III. Process Optimization: Low-Cost Auxiliary Approaches

Beyond directly replacing resins with high-performance alternatives, process-level optimization can effectively amplify the benefits of low-aggregating Protein A resins.

Elution buffer additives represent the most direct optimization approach. Adding PEG and calcium chloride/sodium chloride combinations to the Protein A elution buffer can significantly enhance aggregate removal while maintaining high antibody recovery. Additionally, incorporating 200–500 mM arginine or 1 M urea as protein solubilizers in the elution buffer can effectively prevent precipitation caused by high-density aggregates.

Sodium caprylate washing is another effective strategy. Introducing a sodium caprylate wash step during Protein A chromatography can effectively remove HCP proteases (such as cathepsin D) that cause antibody fragmentation, along with other co-purifying HCPs, reducing fragmentation and associated secondary aggregation risks at the source.

These process optimization methods cannot replace the core function of the resin itself, but they can serve as highly effective auxiliary measures, working synergistically with high-performance low-aggregating Protein A resins/aggregation-reducing Protein A resins to comprehensively mitigate antibody aggregation risks.

IV. Industry Landscape and Selection Recommendations

Currently, low-aggregating Protein A resins and aggregation-reducing Protein A resins have become key innovation areas in the biopharmaceutical chromatography consumables sector. Activity-preserving Protein A resins, as the value expression of this technological direction, are driving the industry toward a conceptual upgrade from "yield pursuit" to "molecular activity preservation."

In the upstream core ligand segment, Matwings Technology has extended its AI-driven protein design capabilities to resin development. Its independently developed MatwingsVenus™ (Xiaowu™) platform, built upon a billion-scale protein sequence dataset (containing billions of functional labels covering sequences from extreme environments such as deep-sea and volcanic sources with high-temperature, high-pressure, and extreme acid/alkali tolerance), can jointly optimize multiple targets including ligand binding capacity, alkali resistance, specificity, and elution conditions. Matwings Technology has clearly identified "alkali-stable Protein A resins" as a core product direction and has established a "dry-wet closed-loop" R&D model powered by MatwingsVenus™, compressing traditional R&D timelines from years to months.

At the ligand product level, GenAlwings' recombinant Protein A products provide solid upstream support for domestic resin manufacturing. Its comprehensive Protein A product line facilitates the industrialization, scale-up, and widespread adoption of domestically produced aggregation-reducing Protein A resins and low-aggregating Protein A resins.

For biopharmaceutical companies planning to introduce low-aggregating Protein A resins or aggregation-reducing Protein A resins, the following evaluation framework is recommended:

Product type and molecular compatibility: Select the appropriate resin based on the structural characteristics of the target antibody molecule. For antibodies containing VH3 domains, VH3-specific low-aggregating Protein A resins enable simultaneous separation of byproducts and aggregates during capture; for pH-sensitive antibodies, high-pH elution aggregation-reducing Protein A resins can prevent aggregate formation at the source.

Aggregate clearance efficiency: Different aggregation-reducing Protein A resins exhibit significant differences in aggregate removal capability; side-by-side comparisons under identical feed conditions are essential, with particular attention to whether the resin achieves "removal of up to 70% of aggregates from the feed."

Dynamic binding capacity and process efficiency: Dynamic binding capacity (DBC) is a core determinant of production costs, provided that aggregate clearance is assured. Mainstream high-pH elution low-aggregating Protein A resins achieve DBC of 60 mg/mL or higher at a 6-minute residence time.

Regulatory and supply chain assurance: Verify whether the supplier provides DMF filings and other regulatory support documents, as well as manufacturing scale capability and batch-to-batch consistency.

V. Conclusion

The New Frontline

Antibody aggregation is an unavoidable quality challenge in biopharmaceutical manufacturing. The traditional purification paradigm relies entirely on downstream polishing steps for aggregate removal, resulting in process lag, high losses, and elevated costs. The emergence of low-aggregating Protein A resins/aggregation-reducing Protein A resins has changed this landscape, shifting the aggregate control frontline to the core capture step.

From engineered ligands enabling mild elution to prevent aggregate formation at the source, to novel ligand specificity enabling simultaneous separation of target products from byproducts—these two technological pathways converge toward the same goal: ensuring that the Protein A capture step not only "captures" antibodies but also "purifies high-quality antibody monomers." The concept of activity-preserving Protein A resins further elevates the focus from "removing the bad" to "protecting the good"—preserving the native conformation and biological function of antibody molecules starting from the capture step through mild elution conditions.

Multiple authoritative academic studies have confirmed that next-generation aggregation-reducing Protein A resins/low-aggregating Protein A resins significantly outperform conventional Protein A resins in aggregate clearance, product yield, and impurity control. As bispecific antibodies, multispecific antibodies, and other complex molecules become the mainstream of R&D, low-aggregating Protein A resins/aggregation-reducing Protein A resins tailored for complex processes will evolve from niche specialty solutions to industry-standard offerings, becoming the next-generation core technology foundation for antibody capture process innovation.